Development of chalcone-like derivatives and their biological and mechanistic investigations as novel influenza nuclear export inhibitors

Liu, Chuanfeng; Zhang, Ying; Li, Ping; Jia, Huinan; Ju, Han; Zhang, Jiwei; Ferreira da Silva-Júnior, Edeildo; Samanta, Sunanda; Kar, Parimal; Huang, Bing; Liu, Xinyong; Zhan, Peng

doi:10.1016/j.ejmech.2023.115845

Cited by 1 publication

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, few novel approaches have emerged. Much of the efforts regarding influenza quality control by SPR involve the integration of these biosensors in-line (Laurent Durous et al 2023 ) or for pharmacokinetic evaluation of influenza drugs which inhibit the actions of viral proteins (Liu et al 2023 ; Ma et al 2024 ). The influenza vaccine distribution pipeline will also benefit from lessons learned during the recent COVID-19 pandemic (Buchy et al 2021 ; Scala et al 2023 ).…”

Section: Perspectives/conclusionmentioning

confidence: 99%

Antibody-independent surface plasmon resonance assays for influenza vaccine quality control

Serafin,

Kamen,

de Crescenzo

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Surface plasmon resonance (SPR)-based biosensors have emerged as a powerful platform for bioprocess monitoring due to their ability to detect biointeractions in real time, without the need for labeling. Paramount for the development of a robust detection platform is the immobilization of a ligand with high specificity and affinity for the in-solution species of interest. Following the 2009 H1N1 pandemic, much effort has been made toward the development of quality control platforms for influenza A vaccine productions, many of which have employed SPR for detection. Due to the rapid antigenic drift of influenza’s principal surface protein, hemagglutinin, antibodies used for immunoassays need to be produced seasonally. The production of these antibodies represents a 6–8-week delay in immunoassay and, thus, vaccine availability. This review focuses on SPR-based assays that do not rely on anti-HA antibodies for the detection, characterization, and quantification of influenza A in bioproductions and biological samples. Key points • The single radial immunodiffusion assay (SRID) has been the gold standard for the quantification of influenza vaccines since 1979. Due to antigenic drift of influenza’s hemagglutinin protein, new antibody reagents for the SRID assay must be produced each year, requiring 6–8 weeks. The resulting delay in immunoassay availability is a major bottleneck in the influenza vaccine pipeline. This review highlights ligand options for the detection and quantification of influenza viruses using surface plasmon resonance biosensors.

show abstract